rotating globe
20 May 2026


NCLT approves ₹8,000-crore SeQuent–Viyash deal

Carlyle-backed SeQuent and Viyash unite to create a stronger global pharma platform

The NCLT has approved the ₹8,000-crore merger of SeQuent Scientific and Viyash Life Sciences, combining animal-health and pharma manufacturing strengths. Viyash shareholders will get 56 SeQuent shares per 100 held. The merged entity will expand global reach and boost R&D and manufacturing capacity.